1
|
Khair AM, Falchek S, Nikam R, Kaur G. Epilepsy and Electroencephalogram Characteristics in Children with Neurofibromatosis Type 1, What We Have Learned from a Tertiary Center Five Years' Experience. Child Neurol Open 2022; 9:2329048X221131445. [PMID: 36249667 PMCID: PMC9554130 DOI: 10.1177/2329048x221131445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 09/12/2022] [Accepted: 09/20/2022] [Indexed: 11/11/2022] Open
Abstract
Introduction: Neurofibromatosis type 1(NF-1) is the commonest neurocutaneous phacomatosis in children. Epilepsy is an infrequent comorbidity. Reports of seizure and Electroencephalogram (EEG) characteristics in children are sparse. Methods: A retrospective review was performed on patients with NF-1 seen between 2016-2020. Patients with co-existing epilepsy were identified. Demographic, clinical, radiological and neurophysiological data were reviewed and analyzed. Results: Out of 118 children with NF1, 16 had epilepsy. 11 patients had focal onset seizures, whereas 5 had generalized onset seizures. Most patients had easy seizure control. Focal epileptiform discharges were the most prevalent EEG abnormality. There was no significant correlation between seizure patterns and presence of intracranial tumors. Conclusion: Epilepsy is a relatively uncommon in pediatric NF-1. Seizures are often of focal semiology and likely to be easily controlled. Focal and multifocal spike epileptiform discharges are the typical interictal EEG findings. Correlation of clinical and EEG findings with intracranial lesions is poor.
Collapse
Affiliation(s)
- Abdulhafeez M. Khair
- Division of Pediatric Neurology, Department of Pediatrics, Nemours Children's Health, Wilmington, DE, USA,Abdulhafeez M. Khair, MD, MHPE, Division of Pediatric Neurology, Department of Pediatrics, Nemours Children's Health, 1600 Rockland Rd, Wilmington, DE 19803-3607, USA.
Emails: ,
| | - Stephen Falchek
- Division of Pediatric Neurology, Department of Pediatrics, Nemours Children's Health, Wilmington, DE, USA
| | - Rahul Nikam
- Division of Neuroradiology, Department of Radiology, Nemours Children's Health, Wilmington, DE, USA
| | - Gurcharanjeet Kaur
- Division of Pediatric Neurology, Department of Pediatrics, Nemours Children's Health, Wilmington, DE, USA
| |
Collapse
|
2
|
Genotype-Phenotype Correlations in Neurofibromatosis Type 1: Identification of Novel and Recurrent NF1 Gene Variants and Correlations with Neurocognitive Phenotype. Genes (Basel) 2022; 13:genes13071130. [PMID: 35885913 PMCID: PMC9316015 DOI: 10.3390/genes13071130] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 06/14/2022] [Accepted: 06/17/2022] [Indexed: 02/01/2023] Open
Abstract
Neurofibromatosis type 1 (NF1) is one of the most common genetic tumor predisposition syndrome, caused by mutations in the NF1. To date, few genotype-phenotype correlations have been discerned in NF1, due to a highly variable clinical presentation. We aimed to study the molecular spectrum of NF1 and genotype-phenotype correlations in a monocentric study cohort of 85 NF1 patients (20 relatives, 65 sporadic cases). Clinical data were collected at the time of the mutation analysis and reviewed for accuracy in this investigation. An internal phenotypic categorization was applied. The 94% of the patients enrolled showed a severe phenotype with at least one systemic complication and a wide range of associated malignancies. Spine deformities were the most common complications in this cohort. We also reported 66 different NF1 mutations, of which 7 are novel mutations. Correlation analysis identified a slight significant inverse correlation between age at diagnosis and delayed acquisition of psychomotor skills with residual multi-domain cognitive impairment. Odds ratio with 95% confidence interval showed a higher prevalence of learning disabilities in patients carrying frameshift mutations. Overall, our results aim to offer an interesting contribution to studies on the genotype–phenotype of NF1 and in genetic management and counselling.
Collapse
|
3
|
Keegan NP, Wilton SD, Fletcher S. Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing. Front Genet 2022; 12:806946. [PMID: 35140743 PMCID: PMC8819188 DOI: 10.3389/fgene.2021.806946] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 12/09/2021] [Indexed: 12/16/2022] Open
Abstract
Understanding pre-mRNA splicing is crucial to accurately diagnosing and treating genetic diseases. However, mutations that alter splicing can exert highly diverse effects. Of all the known types of splicing mutations, perhaps the rarest and most difficult to predict are those that activate pseudoexons, sometimes also called cryptic exons. Unlike other splicing mutations that either destroy or redirect existing splice events, pseudoexon mutations appear to create entirely new exons within introns. Since exon definition in vertebrates requires coordinated arrangements of numerous RNA motifs, one might expect that pseudoexons would only arise when rearrangements of intronic DNA create novel exons by chance. Surprisingly, although such mutations do occur, a far more common cause of pseudoexons is deep-intronic single nucleotide variants, raising the question of why these latent exon-like tracts near the mutation sites have not already been purged from the genome by the evolutionary advantage of more efficient splicing. Possible answers may lie in deep intronic splicing processes such as recursive splicing or poison exon splicing. Because these processes utilize intronic motifs that benignly engage with the spliceosome, the regions involved may be more susceptible to exonization than other intronic regions would be. We speculated that a comprehensive study of reported pseudoexons might detect alignments with known deep intronic splice sites and could also permit the characterisation of novel pseudoexon categories. In this report, we present and analyse a catalogue of over 400 published pseudoexon splice events. In addition to confirming prior observations of the most common pseudoexon mutation types, the size of this catalogue also enabled us to suggest new categories for some of the rarer types of pseudoexon mutation. By comparing our catalogue against published datasets of non-canonical splice events, we also found that 15.7% of pseudoexons exhibit some splicing activity at one or both of their splice sites in non-mutant cells. Importantly, this included seven examples of experimentally confirmed recursive splice sites, confirming for the first time a long-suspected link between these two splicing phenomena. These findings have the potential to improve the fidelity of genetic diagnostics and reveal new targets for splice-modulating therapies.
Collapse
Affiliation(s)
- Niall P. Keegan
- Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA, Australia
- Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, The University of Western Australia, Perth, WA, Australia
- *Correspondence: Niall P. Keegan,
| | - Steve D. Wilton
- Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA, Australia
- Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, The University of Western Australia, Perth, WA, Australia
| | - Sue Fletcher
- Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, WA, Australia
- Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, The University of Western Australia, Perth, WA, Australia
| |
Collapse
|
4
|
Perez-Becerril C, Evans DG, Smith MJ. Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes. Hum Mutat 2021; 42:1187-1207. [PMID: 34273915 DOI: 10.1002/humu.24261] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 06/16/2021] [Accepted: 07/13/2021] [Indexed: 11/11/2022]
Abstract
Neurofibromatosis type 1 (NF1), type 2 (NF2), and schwannomatosis are a group of autosomal dominant disorders that predispose to the development of nerve sheath tumors. Pathogenic variants (PVs) that cause NF1 and NF2 are located in the NF1 and NF2 loci, respectively. To date, most variants associated with schwannomatosis have been identified in the SMARCB1 and LZTR1 genes, and a missense variant in the DGCR8 gene was recently reported to predispose to schwannomas. In spite of the high detection rate for PVs in NF1 and NF2 (over 90% of non-mosaic germline variants can be identified by routine genetic screening) underlying PVs for a proportion of clinical cases remain undetected. A higher proportion of non-NF2 schwannomatosis cases have no detected PV, with PVs currently only identified in around 70%-86% of familial cases and 30%-40% of non-NF2 sporadic schwannomatosis cases. A number of variants of uncertain significance have been observed for each disorder, many of them located in noncoding, regulatory, or intergenic regions. Here we summarize noncoding variants in this group of genes and discuss their established or potential role in the pathogenesis of NF1, NF2, and schwannomatosis.
Collapse
Affiliation(s)
- Cristina Perez-Becerril
- Division of Evolution and Genomic Science, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester Academic Health Science Centre, School of Biological Sciences, University of Manchester, Manchester, UK
| | - D Gareth Evans
- Division of Evolution and Genomic Science, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester Academic Health Science Centre, School of Biological Sciences, University of Manchester, Manchester, UK
| | - Miriam J Smith
- Division of Evolution and Genomic Science, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester Academic Health Science Centre, School of Biological Sciences, University of Manchester, Manchester, UK
| |
Collapse
|
5
|
Büki G, Zsigmond A, Czakó M, Szalai R, Antal G, Farkas V, Fekete G, Nagy D, Széll M, Tihanyi M, Melegh B, Hadzsiev K, Bene J. Genotype-Phenotype Associations in Patients With Type-1, Type-2, and Atypical NF1 Microdeletions. Front Genet 2021; 12:673025. [PMID: 34168676 PMCID: PMC8217751 DOI: 10.3389/fgene.2021.673025] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 05/12/2021] [Indexed: 11/23/2022] Open
Abstract
Neurofibromatosis type 1 is a tumor predisposition syndrome inherited in autosomal dominant manner. Besides the intragenic loss-of-function mutations in NF1 gene, large deletions encompassing the NF1 gene and its flanking regions are responsible for the development of the variable clinical phenotype. These large deletions titled as NF1 microdeletions lead to a more severe clinical phenotype than those observed in patients with intragenic NF1 mutations. Around 5-10% of the cases harbor large deletion and four major types of NF1 microdeletions (type 1, 2, 3 and atypical) have been identified so far. They are distinguishable in term of their size and the location of the breakpoints, by the frequency of somatic mosaicism with normal cells not harboring the deletion and by the number of the affected genes within the deleted region. In our study genotype-phenotype analyses have been performed in 17 mostly pediatric patients with NF1 microdeletion syndrome identified by multiplex ligation-dependent probe amplification after systematic sequencing of the NF1 gene. Confirmation and classification of the NF1 large deletions were performed using array comparative genomic hybridization, where it was feasible. In our patient cohort 70% of the patients possess type-1 deletion, one patient harbors type-2 deletion and 23% of our cases have atypical NF1 deletion. All the atypical deletions identified in this study proved to be novel. One patient with atypical deletion displayed mosaicism. In our study NF1 microdeletion patients presented dysmorphic facial features, macrocephaly, large hands and feet, delayed cognitive development and/or learning difficulties, speech difficulties, overgrowth more often than patients with intragenic NF1 mutations. Moreover, neurobehavior problems, macrocephaly and overgrowth were less frequent in atypical cases compared to type-1 deletion. Proper diagnosis is challenging in certain patients since several clinical manifestations show age-dependency. Large tumor load exhibited more frequently in this type of disorder, therefore better understanding of genotype-phenotype correlations and progress of the disease is essential for individuals suffering from neurofibromatosis to improve the quality of their life. Our study presented additional clinical data related to NF1 microdeletion patients especially for pediatric cases and it contributes to the better understanding of this type of disorder.
Collapse
Affiliation(s)
- Gergely Büki
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary.,Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Anna Zsigmond
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary
| | - Márta Czakó
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary.,Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Renáta Szalai
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary.,Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Gréta Antal
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary
| | - Viktor Farkas
- 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - György Fekete
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Dóra Nagy
- Department of Medical Genetics, Faculty of Medicine, University of Szeged, Szeged, Hungary
| | - Márta Széll
- Department of Medical Genetics, Faculty of Medicine, University of Szeged, Szeged, Hungary
| | - Marianna Tihanyi
- Genetic Laboratory, Szent Rafael Hospital of Zala County, Zalaegerszeg, Hungary
| | - Béla Melegh
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary.,Szentágothai Research Centre, University of Pécs, Pécs, Hungary.,Full member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID No. 739547, Pécs, Hungary
| | - Kinga Hadzsiev
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary.,Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Judit Bene
- Department of Medical Genetics, Clinical Center, Medical School, University of Pécs, Pécs, Hungary.,Szentágothai Research Centre, University of Pécs, Pécs, Hungary.,Full member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID No. 739547, Pécs, Hungary
| |
Collapse
|
6
|
Peces R, Mena R, Martín Y, Hernández C, Peces C, Tellería D, Cuesta E, Selgas R, Lapunzina P, Nevado J. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2. Mol Genet Genomic Med 2020; 8:e1321. [PMID: 32533764 PMCID: PMC7434601 DOI: 10.1002/mgg3.1321] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 04/25/2020] [Accepted: 04/27/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) and neurofibromatosis type 1 (NF1) are both autosomal dominant disorders with a high rate of novel mutations. However, the two disorders have distinct and well-delineated genetic, biochemical, and clinical findings. Only a few cases of coexistence of ADPKD and NF1 in a single individual have been reported, but the possible implications of this association are unknown. METHODS We report an ADPKD male belonging to a family of several affected members in three generations associated with NF1 and optic pathway gliomas. The clinical diagnosis of ADPKD and NF1 was performed by several image techniques. RESULTS Linkage analysis of ADPKD family was consistent to the PKD2 locus by a nonsense mutation, yielding a truncated polycystin-2 by means of next-generation sequencing. The diagnosis of NF1 was confirmed by mutational analysis of this gene showing a 4-bp deletion, resulting in a truncated neurofibromin, as well. The impact of this association was investigated by analyzing putative genetic interactions and by comparing the evolution of renal size and function in the proband with his older brother with ADPKD without NF1 and with ADPKD cohorts. CONCLUSION Despite the presence of both conditions there was not additive effect of NF1 and PKD2 in terms of the severity of tumor development and/or ADPKD progression.
Collapse
Affiliation(s)
- Ramón Peces
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma, Madrid, Spain
| | - Rocío Mena
- Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, Universidad Autónoma, Madrid, Spain.,CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain
| | - Yolanda Martín
- Servicio de Genética, Hospital Universitario Ramón y Cajal, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Concepción Hernández
- Servicio de Genética, Hospital Universitario Ramón y Cajal, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Carlos Peces
- Area de Tecnologías de la Información, SESCAM, Toledo, Spain
| | - Dolores Tellería
- Servicio de Genética, Hospital Universitario Ramón y Cajal, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | - Emilio Cuesta
- Servicio de Radiología, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma, Madrid, Spain
| | - Rafael Selgas
- Servicio de Nefrología, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma, Madrid, Spain
| | - Pablo Lapunzina
- Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, Universidad Autónoma, Madrid, Spain.,CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain
| | - Julián Nevado
- Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, Universidad Autónoma, Madrid, Spain.,CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain
| |
Collapse
|
7
|
Pacot L, Burin des Roziers C, Laurendeau I, Briand-Suleau A, Coustier A, Mayard T, Tlemsani C, Faivre L, Thomas Q, Rodriguez D, Blesson S, Dollfus H, Muller YG, Parfait B, Vidaud M, Gilbert-Dussardier B, Yardin C, Dauriat B, Derancourt C, Vidaud D, Pasmant E. One NF1 Mutation may Conceal Another. Genes (Basel) 2019; 10:genes10090633. [PMID: 31443423 PMCID: PMC6769760 DOI: 10.3390/genes10090633] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 08/10/2019] [Accepted: 08/20/2019] [Indexed: 01/01/2023] Open
Abstract
Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with complete penetrance but high variable expressivity. NF1 is caused by loss-of-function mutations in the NF1 gene, a negative regulator of the RAS-MAPK pathway. The NF1 gene has one of the highest mutation rates in human disorders, which may explain the outbreak of independent de novo variants in the same family. Here, we report the co-occurrence of pathogenic variants in the NF1 and SPRED1 genes in six families with NF1 and Legius syndrome, using next-generation sequencing. In five of these families, we observed the co-occurrence of two independent NF1 variants. All NF1 variants were classified as pathogenic, according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG-AMP) guidelines. In the sixth family, one sibling inherited a complete deletion of the NF1 gene from her mother and carried a variant of unknown significance in the SPRED1 gene. This variant was also present in her brother, who was diagnosed with Legius syndrome, a differential diagnosis of NF1. This work illustrates the complexity of molecular diagnosis in a not-so-rare genetic disease.
Collapse
Affiliation(s)
- Laurence Pacot
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | - Cyril Burin des Roziers
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | - Ingrid Laurendeau
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | - Audrey Briand-Suleau
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | - Audrey Coustier
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
| | - Théodora Mayard
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
| | - Camille Tlemsani
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | - Laurence Faivre
- Inserm, UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne, 21079 Dijon, France
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital d'Enfants, 21079 Dijon, France
| | - Quentin Thomas
- Inserm, UMR 1231, Génétique des Anomalies du Développement, Université de Bourgogne, 21079 Dijon, France
- Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital d'Enfants, 21079 Dijon, France
| | - Diana Rodriguez
- Department of Child Neurology and National Reference Center for Neurogenetic Disorders, Armand Trousseau Hospital, GHUEP, AP-HP, INSERM U1141, 75012 Paris, France
- GRC n°19 ConCer-LD, Sorbonne Université, 75012 Paris, France
| | - Sophie Blesson
- Service de Génétique, CHRU de Tours, 37044 Tours, France
| | - Hélène Dollfus
- Centre de référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpital Civil, 67091 Strasbourg, France
- Service de Génétique Médicale, Hôpital de Hautepierre, 67200 Strasbourg, France
- Laboratoire de Génétique Médicale, INSERM U1112, 67000 Strasbourg, France
| | | | - Béatrice Parfait
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | - Michel Vidaud
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | | | - Catherine Yardin
- Department of Cytogenetics and clinical genetics, Limoges University Hospital, 87042 Limoges, France
- UMR 7252, Limoges University, CNRS, XLIM, 87000 Limoges, France
| | - Benjamin Dauriat
- Department of Cytogenetics and clinical genetics, Limoges University Hospital, 87042 Limoges, France
| | - Christian Derancourt
- EA 4537, Antilles University, 97261 Fort-de-France, Martinique, France
- DRCI, Martinique University Hospital, 97261 Fort-de-France, Martinique, France
| | - Dominique Vidaud
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France
| | - Eric Pasmant
- Service de Génétique et Biologie Moléculaires, Hôpital Cochin, HUPC, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France.
- Institut Cochin, INSERM U1016, Université Paris Descartes, 75014 Paris, France.
| |
Collapse
|
8
|
Wang W, Qin W, Ge H, Kong X, Xie C, Tang Y, Li M. Clinical and molecular characteristics of thirty NF1 variants in Chinese patients with neurofibromatosis type 1. Mol Biol Rep 2019; 46:4349-4359. [PMID: 31201679 DOI: 10.1007/s11033-019-04888-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Accepted: 05/15/2019] [Indexed: 01/29/2023]
Abstract
Neurofibromatosis type 1 (NF1) is a common autosomal dominant tumor-predisposition disorder that mainly impacts the nervous system and skin. Since the full clinical presentation of NF1 depends on age, it can be difficult to make an early and definite diagnosis in paediatric patients without family history who only exhibited multiple cafè-au-lait spots, highlighting the need for mutational analysis. A combination of techniques was conducted in 30 families with NF1, including multi-gene panels, direct sequencing, cDNA sequencing and multiplex ligation-dependent probe amplification. Thirty variants were identified in 36 patients from the 30 families, among which ten variants were novel. As a result, we confirmed that the combination of techniques were highly accurate and sensitive for identifying pathogenic variants in patients clinically suspected of having NF1, in particular, for patients who only present with multiple cafè-au-lait spots.
Collapse
Affiliation(s)
- Wen Wang
- Departments of Dermatology and Venereology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Weibing Qin
- NHC Key Laboratory of Male Reproduction and Genetics, Family Planning Research Institute of Guangdong Province, Guangzhou, China
| | - Hongsong Ge
- Departments of Dermatology, Anhui Provincial Children's Hospital, Hefei, Anhui, China
| | | | - Chao Xie
- Department of Paediatrics, The First People's Hospital of Hefei, Hefei, Anhui, China
| | - Yunge Tang
- NHC Key Laboratory of Male Reproduction and Genetics, Family Planning Research Institute of Guangdong Province, Guangzhou, China.
| | - Ming Li
- Departments of Dermatology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| |
Collapse
|
9
|
Palma Milla C, Lezana Rosales JM, López Montiel J, Andrés Garrido LD, Sánchez Linares C, Carmona Tamajón S, Torres Fernández C, Sánchez González P, Franco Freire S, Benito López C, López Siles J. Neurofibromatosis type I: mutation spectrum of NF1 in spanish patients. Ann Hum Genet 2018; 82:425-436. [PMID: 30014477 DOI: 10.1111/ahg.12272] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 05/19/2018] [Accepted: 06/18/2018] [Indexed: 01/07/2023]
Abstract
Neurofibromatosis type I (NF1) is one of the most common genetic disorders in humans. NF1, a tumor predisposition syndrome, is caused by heterozygous pathogenic variants in the NF1 gene. Molecular genetic testing of NF1 is complex, especially because of the presence of a high number of partial pseudogenes, some of them with a high percentage of sequence identity. In this study, we have analyzed the largest cohort of NF1 Spanish patients (150 unrelated individuals suspected of having NF1 and 53 relatives, making a total of 203 individuals). Mutation analysis of the entire coding region was performed in all unrelated index patients. Additionally, the Multiplex Ligation-dependent Probe Amplification (MLPA) test of the NF1 gene and SPRED1 gene analysis (sequencing and MLPA test) was performed in some of the negative patients for NF1 point mutations. When fulfilling the National Institutes of Health (NIH) criterion for the clinical diagnosis of NF1, the detection rate was 79%. Among the 80 genetically confirmed NF1 probands, we detected 69 different pathogenic variants. Two mutations (3%) were gross deletions of the whole gene, the remaining 78 mutations (97%) were small changes spread among all NF1 exons. Among these 69 different mutations detected, 42 mutations were described elsewhere, and 27 mutations were novel mutations. When segregation was studied, 67% of mutations resulted de novo variants. No genetic mosaicism was detected on patients' parents.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Sara Franco Freire
- Hospital Regional Universitario de Málaga. U.G.C. de Laboratorio. Sección de Genética
| | - Carmen Benito López
- Hospital Regional Universitario de Málaga. U.G.C. de Laboratorio. Sección de Genética
| | | |
Collapse
|
10
|
Santoro C, Bernardo P, Coppola A, Pugliese U, Cirillo M, Giugliano T, Piluso G, Cinalli G, Striano S, Bravaccio C, Perrotta S. Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough? Ital J Pediatr 2018; 44:41. [PMID: 29566708 PMCID: PMC5863905 DOI: 10.1186/s13052-018-0477-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 03/09/2018] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Neurofibromatosis type 1 (NF1) is related to a generally increased prevalence of seizures. The mechanism underlying the increased predisposition to seizures has not been fully elucidated. The aim of the study was to evaluate the role of NF1 in seizures pathogenesis in a cohort of children with NF1 and seizures. METHODS The medical records of 437 children (0-18 years old) with NF1 were reviewed. All children with at least one afebrile seizure were included. Demographic, clinical, neurological, NF1 mutation status, and EEG data were collected along with brain magnetic resonance imaging. Depending on etiology, structural seizures have been identified and were further classified as NF1 related or not. RESULTS Nineteen patients (4.3%; 13 males) were included. NF1 was inherited in 7 (37.5%), with 3 maternal forms. Ten children with structural seizures were identified. Seven forms were identified someway related to NF1, two of which were associated to 17q11.2 microdeletion and hypoxic-ischemic encephalopathy. Any brain lesion that could explain seizures was found in nine patients, two third of these patients had a familiar history of epilepsy. CONCLUSIONS Our results suggest seizures are more frequent in NF1 children (4.3%) than in general pediatric population (0.3-0.5%) and that are someway related to NF1 in half of patients. Facing seizures in NF1, the clinician should first exclude brain tumors but also other, and rarer NF1-related scenarios, such as hydrocephalous and vasculopathies. Children with non-structural seizures frequently had a family history of epilepsy, raising questions about the pathogenic role of NF1. They should be approached as for the general population.
Collapse
Affiliation(s)
- Claudia Santoro
- Centro di Riferimento Pediatrico delle Neurofibromatosi, Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università degli Studi della Campania "L. Vanvitelli", Caserta, Italy.
| | - Pia Bernardo
- Dipartimento di Scienze Mediche Traslazionali, Università "Federico II", Napoli, Italy.,Centro Epilessia. Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università Federico II, Naples, Italy
| | - Antonietta Coppola
- Centro Epilessia. Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università Federico II, Naples, Italy
| | - Umberto Pugliese
- Centro di Riferimento Pediatrico delle Neurofibromatosi, Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università degli Studi della Campania "L. Vanvitelli", Caserta, Italy
| | - Mario Cirillo
- Dipartimento di Scienze Mediche, Chirurgiche, Neurologiche, Metaboliche e dell'invecchiamento, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy
| | - Teresa Giugliano
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy
| | - Giulio Piluso
- Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy
| | - Giuseppe Cinalli
- Dipartimento di Neurochirurgia, Santobono-Pausilipon Children's Hospital, Naples, Italy
| | - Salvatore Striano
- Centro Epilessia. Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università Federico II, Naples, Italy
| | - Carmela Bravaccio
- Dipartimento di Scienze Mediche Traslazionali, Università "Federico II", Napoli, Italy
| | - Silverio Perrotta
- Centro di Riferimento Pediatrico delle Neurofibromatosi, Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università degli Studi della Campania "L. Vanvitelli", Caserta, Italy
| |
Collapse
|
11
|
Bianchessi D, Morosini S, Saletti V, Ibba MC, Natacci F, Esposito S, Cesaretti C, Riva D, Finocchiaro G, Eoli M. 126 novel mutations in Italian patients with neurofibromatosis type 1. Mol Genet Genomic Med 2015; 3:513-25. [PMID: 26740943 PMCID: PMC4694136 DOI: 10.1002/mgg3.161] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Revised: 05/25/2015] [Accepted: 06/01/2015] [Indexed: 12/31/2022] Open
Abstract
Genetic analysis of Neurofibromatosis type 1 (NF1) may facilitate the identification of patients in early phases of the disease. Here, we present an overview of our diagnostic research spanning the last 11 years, with a focus on the description of 225 NF1 mutations, 126 of which are novel, found in a series of 607 patients (513 unrelated) in Italy. Between 2003 and 2013, 443 unrelated patients were profiled by denaturing high pressure liquid chromatography (DHPLC) analysis of 60 amplicons derived from genomic NF1DNA and subsequent sequencing of heterozygotic PCR products. In addition, a subset of patients was studied by multiplex ligation‐dependent probe amplification (MLPA) to identify any duplications, large deletions or microdeletions present at the locus. Over the last year, 70 unrelated patients were investigated by MLPA and sequencing of 22 amplicons spanning the entire NF1cDNA. Mutations were found in 70% of the 293 patients studied by DHPLC, thereby fulfilling the NIH criterion for the clinical diagnosis of NF1 (detection rate: 70%); furthermore, 87% of the patients studied by RNA sequencing were genetically characterized. Mutations were also found in 36 of the 159 patients not fulfilling the NIH clinical criteria. We confirmed a higher incidence of intellectual disability in patients harboring microdeletion type 1 and observed a correlation between a mild phenotype and the small deletion c.2970_2972delAAT or the missense alteration in amino acid residue 1809 (p.Arg1809Cys). These data support the use of RNA‐based methods for genetic analysis and provide novel information for improving the management of symptoms in oligosymptomatic patients.
Collapse
Affiliation(s)
- Donatella Bianchessi
- Molecular Neuro-oncology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| | - Sara Morosini
- Molecular Neuro-oncology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| | - Veronica Saletti
- Developmental Neurology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| | - Maria Cristina Ibba
- Molecular Neuro-oncology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| | - Federica Natacci
- Medical Genetics IRCSS Foundation, Cà Grande-Ospedale Maggiore Policlinico Milan Italy
| | - Silvia Esposito
- Developmental Neurology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| | - Claudia Cesaretti
- Medical Genetics IRCSS Foundation, Cà Grande-Ospedale Maggiore Policlinico Milan Italy
| | - Daria Riva
- Developmental Neurology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| | - Gaetano Finocchiaro
- Molecular Neuro-oncology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| | - Marica Eoli
- Molecular Neuro-oncology IRCCS Foundation, "C. Besta" Neurological Institute Milan Italy
| |
Collapse
|
12
|
Jo YH, Kim HO, Song HR, Yoon KS. Identification of the NF1 gene mutation in Korean families with neurofibromatosis type 1. Genes Genomics 2014. [DOI: 10.1007/s13258-013-0132-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Burkitt Wright EM, Sach E, Sharif S, Quarrell O, Carroll T, Whitehouse RW, Upadhyaya M, Huson SM, Evans DGR. Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis. J Med Genet 2013; 50:606-13. [PMID: 23812910 PMCID: PMC3756527 DOI: 10.1136/jmedgenet-2013-101648] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND Consensus clinical diagnostic criteria for neurofibromatosis type I (NF1) include café-au-lait macules and skinfold freckling. The former are frequently the earliest manifestation of NF1, and as such are of particular significance when assessing young children at risk of the condition. A phenotype of predominantly spinal neurofibromatosis has been identified in a small minority of families with NF1, often in association with a relative or absolute lack of cutaneous manifestations. An association with splicing and missense mutations has previously been reported for spinal neurofibromatosis, but on the basis of molecular results in only a few families. METHOD Patients with spinal NF1 were identified through the Manchester nationally commissioned service for complex NF1. RESULTS Five families with spinal NF1 were identified, with a broad spectrum of NF1 mutations, providing further evidence that this phenotype may arise in association with any genre of mutation in this gene. Pigmentary manifestations were absent or very mild in affected individuals. Several further affected individuals, some with extensive spinal root tumours, were ascertained when additional family members were assessed. CONCLUSIONS Clinical NF1 consensus criteria cannot be used to exclude the diagnosis of spinal NF1, especially in childhood. This emphasises the importance of molecular confirmation in individuals and families with atypical presentations of NF1.
Collapse
Affiliation(s)
- Emma Mm Burkitt Wright
- Genetic Medicine Research Group, Faculty of Medical and Human Sciences, Institute of Human Development, University of Manchester, Manchester, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Thomas L, Spurlock G, Eudall C, Thomas NS, Mort M, Hamby SE, Chuzhanova N, Brems H, Legius E, Cooper DN, Upadhyaya M. Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas. Eur J Hum Genet 2011; 20:411-9. [PMID: 22108604 DOI: 10.1038/ejhg.2011.207] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Neurofibromatosis type-1 (NF1), caused by heterozygous inactivation of the NF1 tumour suppressor gene, is associated with the development of benign and malignant peripheral nerve sheath tumours (MPNSTs). Although numerous germline NF1 mutations have been identified, relatively few somatic NF1 mutations have been described in neurofibromas. Here we have screened 109 cutaneous neurofibromas, excised from 46 unrelated NF1 patients, for somatic NF1 mutations. NF1 mutation screening (involving loss-of-heterozygosity (LOH) analysis, multiplex ligation-dependent probe amplification and DNA sequencing) identified 77 somatic NF1 point mutations, of which 53 were novel. LOH spanning the NF1 gene region was evident in 25 neurofibromas, but in contrast to previous data from MPNSTs, it was absent at the TP53, CDKN2A and RB1 gene loci. Analysis of DNA/RNA from neurofibroma-derived Schwann cell cultures revealed NF1 mutations in four tumours whose presence had been overlooked in the tumour DNA. Bioinformatics analysis suggested that four of seven novel somatic NF1 missense mutations (p.A330T, p.Q519P, p.A776T, p.S1463F) could be of functional/clinical significance. Functional analysis confirmed this prediction for p.S1463F, located within the GTPase-activating protein-related domain, as this mutation resulted in a 150-fold increase in activated GTP-bound Ras. Comparison of the relative frequencies of the different types of somatic NF1 mutation observed with those of their previously reported germline counterparts revealed significant (P=0.001) differences. Although non-identical somatic mutations involving either the same or adjacent nucleotides were identified in three pairs of tumours from the same patients (P<0.0002), no association was noted between the type of germline and somatic NF1 lesion within the same individual.
Collapse
Affiliation(s)
- Laura Thomas
- Institute of Medical Genetics, School of Medicine, Cardiff University, Heath Park Way, Cardiff, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Staser K, Yang FC, Clapp DW. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. ANNUAL REVIEW OF PATHOLOGY 2011; 7:469-95. [PMID: 22077553 PMCID: PMC3694738 DOI: 10.1146/annurev-pathol-011811-132441] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Neurofibromatosis type 1 (NF1) is a genetic disease that results from either heritable or spontaneous autosomal dominant mutations in the NF1 gene. A second-hit mutation precedes the predominant NF1 neoplasms, which include myeloid leukemia, optic glioma, and plexiform neurofibroma. Despite this requisite NF1 loss of heterozygosity in the tumor cell of origin, nontumorigenic cells contribute to both generalized and specific disease manifestations. In mouse models of plexiform neurofibroma formation, Nf1 haploinsufficient mast cells promote inflammation, accelerating tumor formation and growth. These recruited mast cells, hematopoietic effector cells long known to permeate neurofibroma tissue, mediate key mitogenic signals that contribute to vascular ingrowth, collagen deposition, and tumor growth. Thus, the plexiform neurofibroma microenvironment involves a tumor/stromal interaction with the hematopoietic system that depends, at the molecular level, on a stem cell factor/c-kit-mediated signaling axis. These observations parallel findings in other NF1 disease manifestations and are clearly relevant to medical management of these neurofibromas.
Collapse
Affiliation(s)
- Karl Staser
- Department of Biochemistry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
| | | | | |
Collapse
|
16
|
Cunha KSG, Barboza EP, da Fonseca EC. Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics (Sao Paulo) 2008; 63:39-42. [PMID: 18297205 PMCID: PMC2664176 DOI: 10.1590/s1807-59322008000100008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2007] [Accepted: 10/19/2007] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVE The aim of this study was to investigate the presence of growth hormone receptor in plexiform neurofibromas of neurofibromatosis type 1 patients. INTRODUCTION The development of multiple neurofibromas is one of the major features of neurofibromatosis type 1. Since neurofibromas commonly grow during periods of hormonal change, especially during puberty and pregnancy, it has been suggested that hormones may influence neurofibromatosis type 1 neurofibromas. A recent study showed that the majority of localized neurofibromas from neurofibromatosis type 1 patients have growth hormone receptor. METHODS Growth hormone receptor expression was investigated in 5 plexiform neurofibromas using immunohistochemistry. RESULTS Four of the 5 plexiform neurofibromas were immunopositive for growth hormone receptor. CONCLUSION This study suggests that growth hormone may influence the development of plexiform neurofibromas in patients with neurofibromatosis type 1.
Collapse
Affiliation(s)
| | - Eliane Porto Barboza
- Fluminense Federal University, Medicine School, Postgraduate program of pathology – Niterói/RJ, Brazil.
| | | |
Collapse
|
17
|
Griffiths S, Thompson P, Frayling I, Upadhyaya M. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer 2007; 6:21-34. [PMID: 16944272 DOI: 10.1007/s10689-006-9001-3] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2006] [Accepted: 07/11/2006] [Indexed: 11/30/2022]
Abstract
Our experience of providing an NF1 gene diagnostic mutation detection service as part of the U.K. Genetic Testing Network (UKGTN) is presented. A total of 169 unrelated individuals suspected of having neurofibromatosis type I (NF1) were referred for NF1 diagnostic testing over a 2 year period. Mutation analysis of the entire NF1 coding region and the flanking splice sites was carried out, and included the use of a combination of FISH, dHPLC and MLPA. Possible disease causing mutations were identified in 109 (64%) cases. These comprised 88 different sequence alterations, of which 57 were novel. Out of the 169 cases referred, there were 102 patients with reliable clinical data, of whom 78 satisfied the NIH diagnostic criteria for NF1. Within this better defined cohort of NF1 patients, NF1 mutations were identified in 61 individuals (78%), showing the importance of clinical selection on overall test sensitivity, and highlighting the problem of full clinical data collection in the audit of routine services. As mutation detection technologies advance, facilitating direct sequencing of all coding and flanking non-coding regions of the NF1 gene, the development of an even more cost-effective, quick and sensitive diagnostic test for future testing of NF1 is discussed.
Collapse
Affiliation(s)
- Siân Griffiths
- Institute of Medical Genetics, University Hospital of Wales, Cardiff CF14 4XN, UK
| | | | | | | |
Collapse
|
18
|
Weisfeld-Adams JD, Dutton GN, Murphy DM. Vincristine sulfate as a possible cause of optic neuropathy. Pediatr Blood Cancer 2007; 48:238-40. [PMID: 16206187 DOI: 10.1002/pbc.20638] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A 6-year-old boy with skin lesions suggestive of neurofibromatosis developed a frontotemporal primitive neuroectodermal tumor and was subsequently treated with surgery, craniospinal irradiation, and chemotherapy. After the sixth cycle of treatment with vincristine sulfate, 9 months after diagnosis, the child developed a rapidly progressive bilateral deterioration in visual acuity. Retinal appearances were consistent with optic neuropathy. Gene studies for neurocutaneous syndromes were negative. Brain imaging at this time showed no tumor progression, and in the absence of other etiologies, we implicate vincristine as a probable cause. Discontinuation of this particular agent has allowed bilateral improvement in visual acuity.
Collapse
Affiliation(s)
- James D Weisfeld-Adams
- Departments of Paediatric Haematology and Oncology, Royal Hospital for Sick Children, Glasgow, United Kingdom.
| | | | | |
Collapse
|
19
|
Abstract
Neurofibromatosis types 1 and 2 (NF1 and NF2) are autosomal dominant phakomatoses. The NF1 and NF2 genes encode for neurofibromin and merlin, respectively. These 2 functionally unrelated proteins both act as tumor suppressor genes, possibly through modulation of the RAS/RAC oncogenic pathways. Improved understanding of the mechanisms by which these tumor suppressors act may allow for medical therapies for neurofibromatosis and may offer insights for cancer therapeutics.
Collapse
Affiliation(s)
- Kaleb H Yohay
- Division of Child Neurology and Pediatrics, Johns Hopkins University, Baltimore, MD 21287, USA.
| |
Collapse
|
20
|
De Luca A, Bottillo I, Sarkozy A, Carta C, Neri C, Bellacchio E, Schirinzi A, Conti E, Zampino G, Battaglia A, Majore S, Rinaldi MM, Carella M, Marino B, Pizzuti A, Digilio MC, Tartaglia M, Dallapiccola B. NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 2005; 77:1092-101. [PMID: 16380919 PMCID: PMC1285166 DOI: 10.1086/498454] [Citation(s) in RCA: 107] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2005] [Accepted: 09/23/2005] [Indexed: 11/03/2022] Open
Abstract
Neurofibromatosis type 1 (NF1) demonstrates phenotypic overlap with Noonan syndrome (NS) in some patients, which results in the so-called neurofibromatosis-Noonan syndrome (NFNS). From a genetic point of view, NFNS is a poorly understood condition, and controversy remains as to whether it represents a variable manifestation of either NF1 or NS or is a distinct clinical entity. To answer this question, we screened a cohort with clinically well-characterized NFNS for mutations in the entire coding sequence of the NF1 and PTPN11 genes. Heterozygous NF1 defects were identified in 16 of the 17 unrelated subjects included in the study, which provides evidence that mutations in NF1 represent the major molecular event underlying this condition. Lesions included nonsense mutations, out-of-frame deletions, missense changes, small inframe deletions, and one large multiexon deletion. Remarkably, a high prevalence of inframe defects affecting exons 24 and 25, which encode a portion of the GAP-related domain of the protein, was observed. On the other hand, no defect in PTPN11 was observed, and no lesion affecting exons 11-27 of the NF1 gene was identified in 100 PTPN11 mutation-negative subjects with NS, which provides further evidence that NFNS and NS are genetically distinct disorders. These results support the view that NFNS represents a variant of NF1 and is caused by mutations of the NF1 gene, some of which have been demonstrated to cause classic NF1 in other individuals.
Collapse
Affiliation(s)
- Alessandro De Luca
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Irene Bottillo
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Anna Sarkozy
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Claudio Carta
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Cinzia Neri
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Emanuele Bellacchio
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Annalisa Schirinzi
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Emanuela Conti
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Giuseppe Zampino
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Agatino Battaglia
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Silvia Majore
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Maria M. Rinaldi
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Massimo Carella
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Bruno Marino
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Antonio Pizzuti
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Maria Cristina Digilio
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Marco Tartaglia
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| | - Bruno Dallapiccola
- CSS Hospital, IRCCS, San Giovanni Rotondo and CSS-Mendel Institute, Department of Experimental Medicine and Pathology and Section of Pediatric Cardiology, Department of Pediatrics, University “La Sapienza,” Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore, AO San Camillo-Forlanini, and Medical Genetics, Bambino Gesù Hospital, IRCCS, Rome; Stella Maris Scientific Research Institute, Calambrone, Pisa; Genetica Medica, Ospedale Cardarelli, Naples, Italy; and Department of Pediatrics, Mount Sinai School of Medicine, New York
| |
Collapse
|
21
|
Paulson HL. Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations. Neurol Clin 2002; 20:627-43, v. [PMID: 12432824 DOI: 10.1016/s0733-8619(02)00009-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Genetics has emphatically entered the practice of neurology. The last decade witnessed the discovery of the genetic basis of many diseases that primarily affect the nervous system. In areas such as neuromuscular and movement disorders, genetic testing has become a routine part of diagnostic testing. In areas like epilepsy, genetic advances likely will lead to new testing for certain patients. In dementia, the existence of a common predisposing genetic factor (apolipoprotein E) has already raised complex issues such as the appropriateness of genetic testing in specific clinical situations--issues that neurologists will confront more in the future. This article reviews basic principles of genetic testing, its application to neurology, and some limitations and ethical issues confronting the field.
Collapse
Affiliation(s)
- Henry L Paulson
- Department of Neurology, University of Iowa School of Medicine, Iowa City, IA 52242, USA.
| |
Collapse
|
22
|
Abstract
Neurofibromatosis 1 is a progressive autosomal dominant condition caused by mutations in the NF1 gene on chromosome 17. The condition shows clinical variable expressivity, with varying features even between family members who share the same mutation. Furthermore, it is impossible to precisely predict the severity and course of the condition, a source of frustration for families and physicians. Neurofibromatosis 1 is also heterogeneous at the mutation level, with more than 300 independent mutations having been reported in this gene. The mutation data have accumulated slowly owing to the variability of the mutation types and the size and complexity of the gene. This is also reflected in the lack of a simple, inexpensive, highly accurate DNA-based test for neurofibromatosis 1 at present. This article reviews current NF1 mutation spectrum and testing, discussing and illustrating mutation mechanisms and pathogenetic effects, as well as factors affecting DNA testing and interpretation/diagnosis.
Collapse
Affiliation(s)
- Susanne A M Thomson
- Department of Molecular Genetics, University of Florida College of Medicine, Gainesville 32610-0266, USA
| | | | | |
Collapse
|
23
|
Mukhopadhyay D, Anant S, Lee RM, Kennedy S, Viskochil D, Davidson NO. C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am J Hum Genet 2002; 70:38-50. [PMID: 11727199 PMCID: PMC384902 DOI: 10.1086/337952] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2001] [Accepted: 10/05/2001] [Indexed: 11/03/2022] Open
Abstract
C-->U RNA editing of neurofibromatosis 1 (NF1) mRNA changes an arginine (CGA) to a UGA translational stop codon, predicted to result in translational termination of the edited mRNA. Previous studies demonstrated varying degrees of C-->U RNA editing in peripheral nerve-sheath tumor samples (PNSTs) from patients with NF1, but the basis for this heterogeneity was unexplained. In addition, the role, if any, of apobec-1, the catalytic deaminase that mediates C-->U editing of mammalian apolipoprotein B (apoB) RNA, was unresolved. We have examined these questions in PNSTs from patients with NF1 and demonstrate that a subset (8/34) manifest C-->U editing of RNA. Two distinguishing characteristics were found in the PNSTs that demonstrated editing of NF1 RNA. First, these tumors express apobec-1 mRNA, the first demonstration, in humans, of its expression beyond the luminal gastrointestinal tract. Second, PNSTs with C-->U editing of RNA manifest increased proportions of an alternatively spliced exon, 23A, downstream of the edited base. C-->U editing of RNA in these PNSTs was observed preferentially in transcripts containing exon 23A. These findings were complemented by in vitro studies using synthetic RNA templates incubated in the presence of recombinant apobec-1, which again confirmed preferential editing of transcripts containing exon 23A. Finally, adenovirus-mediated transfection of HepG2 cells revealed induction of editing of apoB RNA, along with preferential editing of NF1 transcripts containing exon 23A. Taken together, the data support the hypothesis that C-->U RNA editing of the NF1 transcript occurs both in a subset of PNSTs and in an alternatively spliced form containing a downstream exon, presumably an optimal configuration for enzymatic deamination by apobec-1.
Collapse
Affiliation(s)
- Debnath Mukhopadhyay
- Departments of Medicine and Pharmacology and Molecular Biology, Washington University Medical School, St. Louis; and Department of Pediatrics, Division of Medical Genetics, University of Utah Health Science Center, Salt Lake City
| | - Shrikant Anant
- Departments of Medicine and Pharmacology and Molecular Biology, Washington University Medical School, St. Louis; and Department of Pediatrics, Division of Medical Genetics, University of Utah Health Science Center, Salt Lake City
| | - Robert M. Lee
- Departments of Medicine and Pharmacology and Molecular Biology, Washington University Medical School, St. Louis; and Department of Pediatrics, Division of Medical Genetics, University of Utah Health Science Center, Salt Lake City
| | - Susan Kennedy
- Departments of Medicine and Pharmacology and Molecular Biology, Washington University Medical School, St. Louis; and Department of Pediatrics, Division of Medical Genetics, University of Utah Health Science Center, Salt Lake City
| | - David Viskochil
- Departments of Medicine and Pharmacology and Molecular Biology, Washington University Medical School, St. Louis; and Department of Pediatrics, Division of Medical Genetics, University of Utah Health Science Center, Salt Lake City
| | - Nicholas O. Davidson
- Departments of Medicine and Pharmacology and Molecular Biology, Washington University Medical School, St. Louis; and Department of Pediatrics, Division of Medical Genetics, University of Utah Health Science Center, Salt Lake City
| |
Collapse
|
24
|
Abstract
Type 1 neurofibromatosis (NF1) is an autosomal dominant disorder with an incidence of about 1 in 3500 live births. Symptoms are highly variable from a few cafè-au-lait spots and axillary freckling to plexiform neurofibromas, optic gliomas, pseudarthrosis, and malignancy. Since disease causing mutations are dispersed throughout the gene, prenatal diagnosis is usually performed in familial cases by linkage analysis and rarely by direct characterization of the mutation. We have characterized 48 families and have performed four prenatal diagnoses. In three cases, the linkage analysis was carried out using informative markers. A direct approach using the protein truncation test (PTT) and sequencing was performed in one case in which a R1947X mutation was identified. The extreme variability of the phenotypic expression of the NF1 gene makes reproductive decisions in NF1 families very difficult, as molecular diagnosis cannot predict clinical expression of the disease. The psychological management of the couple is therefore difficult. In two of the three examined families the reproductive choices were not influenced by the specific manifestations of the disease in that family.
Collapse
Affiliation(s)
- P Origone
- Department of Oncology, Biology and Genetics, University of Genoa, Italy.
| | | | | | | | | | | |
Collapse
|
25
|
Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, Paepe AD. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000; 15:541-55. [PMID: 10862084 DOI: 10.1002/1098-1004(200006)15:6<541::aid-humu6>3.0.co;2-n] [Citation(s) in RCA: 331] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant disorders and is caused by mutations in the NF1 gene. Mutation detection is complex due to the large size of the NF1 gene, the presence of pseudogenes and the great variety of possible lesions. Although there is no evidence for locus heterogeneity in NF1, mutation detection rates rarely exceed 50%. We studied 67 unrelated NF1 patients fulfilling the NIH diagnostic criteria, 29 familial and 38 sporadic cases, using a cascade of complementary techniques. We performed a protein truncation test starting from puromycin-treated EBV cell lines and, if no mutation was found, continued with heteroduplex, FISH, Southern blot and cytogenetic analysis. We identified the germline mutation in 64 of 67 patients and 32 of the mutations are novel. This is the highest mutation detection rate reported in a study of typical NF1 patients. All mutations were studied at the genomic and RNA level. The mutational spectrum consisted of 25 nonsense, 12 frameshift, 19 splice mutations, six missense and/or small in-frame deletions, one deletion of the entire NF1 gene, and a translocation t(14;17)(q32;q11.2). Our data suggest that exons 10a-10c and 37 are mutation-rich regions and that together with some recurrent mutations they may account for almost 30% of the mutations in classical NF1 patients. We found a high frequency of unusual splice mutations outside of the AG/GT 5 cent and 3 cent splice sites. As some of these mutations form stable transcripts, it remains possible that a truncated neurofibromin is formed.
Collapse
Affiliation(s)
- L M Messiaen
- Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Rutka JT, Taylor M, Mainprize T, Langlois A, Ivanchuk S, Mondal S, Dirks P. Molecular biology and neurosurgery in the third millennium. Neurosurgery 2000; 46:1034-51. [PMID: 10807235 DOI: 10.1097/00006123-200005000-00002] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The application of techniques in molecular biology to human neurosurgical conditions has led to an increased understanding of disease processes that affect the brain and to novel forms of therapy that favorably modify the natural history of many of these conditions. Molecular strategies are currently being either used or sought for brain tumors, stroke, neurodegenerative diseases, vascular malformations, spinal degenerative diseases, and congenital malformations of the central nervous system. Considering that the structure of deoxyribonucleic acid was ascertained by Watson and Crick as recently as 1953, the progress that has been made to implement molecular medicine in clinical practice has been meteoric. More than 2000 patients have been treated in approved gene therapy trials throughout the world. Many of these patients have been treated for neurological diseases for which conventional medical therapies have been of limited utility. As part of this continuing series on advances in neurosurgery in the third millennium, we first reflect on the history of the nascent field of molecular biology. We then describe the powerful techniques that have evolved from knowledge in this field and have been used in many publications in Neurosurgery, particularly within the past decade. These methods include commonly used techniques such as advanced cytogenetics, differential display, microarray technology, molecular cell imaging, yeast two-hybrid assays, gene therapy, and stem cell utilization. We conclude with a description of the rapidly growing field of bioinformatics. Because the Human Genome Project will be completed within 5 years, providing a virtual blueprint of the human race, the next frontier (and perhaps our greatest challenge) will involve the development of the field of "proteomics," in which protein structure and function are determined from the deoxyribonucleic acid blueprint. It is our conviction that neurosurgeons will continue to be at the forefront of the treatment of patients with neurological diseases using molecular strategies, by performing essential research leading to increased understanding of diseases, by conducting carefully controlled studies to test the effects of treatments on disease processes, and by directly administering (by neurosurgical, endovascular, endoscopic, or stereotactic means) the treatments to patients.
Collapse
|
27
|
Ars E, Serra E, de la Luna S, Estivill X, Lázaro C. Cold shock induces the insertion of a cryptic exon in the neurofibromatosis type 1 (NF1) mRNA. Nucleic Acids Res 2000; 28:1307-12. [PMID: 10684924 PMCID: PMC111054 DOI: 10.1093/nar/28.6.1307] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/1999] [Revised: 02/02/2000] [Accepted: 02/02/2000] [Indexed: 11/14/2022] Open
Abstract
Alternative splicing is a regulatory process of gene expression based on the flexibility in the selection of splice sites. In this manuscript we present the characterisation of an alternative splicing of the NF1 pre-mRNA induced by cold-shock conditions. We demonstrate that the accuracy of the splicing mechanism was perturbed after keeping samples for a short period of time at room temperature, resulting in the insertion of a 31-bp cryptic exon between exons 4a and 4b of the NF1 mRNA. This alternative splicing is not cell type specific and is not induced by other stress conditions such as heat shock or hyper-osmolarity. The alternative spliced mRNA is efficiently transported to the cytoplasm and it is proven to belong to the poly A(+)mRNA fraction. Previous misleading interpretations about this transcript, together with our finding relating its presence to cold shock and not to the NF1 disease, strongly indicate that this phenomenon should be taken into account in genetic testing when RNA methodology is used for mutation detection. This is the first description of an alternative splicing induced by cold shock in a human pre-mRNA and should provide further insights into the factors that control alternative splicing.
Collapse
Affiliation(s)
- E Ars
- Medical and Molecular Genetics Center-IRO, Hospital Duran i Reynals, Avia. Castelldefels, Km 2.7, L'Hospitalet de Llobregat, 08907-Barcelona, Spain
| | | | | | | | | |
Collapse
|
28
|
Eisenbarth I, Beyer K, Krone W, Assum G. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am J Hum Genet 2000; 66:393-401. [PMID: 10677298 PMCID: PMC1288091 DOI: 10.1086/302747] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Neurofibromatosis type 1 (NF1), a common autosomal dominant disorder caused by mutations of the NF1 gene, is characterized by multiple neurofibromas, pigmentation anomalies, and a variety of other possible complications, including an increased risk of malignant neoplasias. Tumorigenesis in NF1 is believed to follow the two-hit hypothesis postulated for tumor-suppressor genes. Loss of heterozygosity (LOH) has been shown to occur in NF1-associated malignancies and in benign neurofibromas, but only few of the latter yielded a positive result. Here we describe a systematic approach of searching for somatic inactivation of the NF1 gene in neurofibromas. In the course of these studies, two new intragenic polymorphisms of the NF1 gene, a tetranucleotide repeat and a 21-bp duplication, could be identified. Three tumor-specific point mutations and two LOH events were detected among seven neurofibromas from four different NF1 patients. Our results suggest that small subtle mutations occur with similar frequency to that of LOH in benign neurofibromas and that somatic inactivation of the NF1 gene is a general event in these tumors. The spectrum of somatic mutations occurring in various tumors from individual NF1 patients may contribute to the understanding of variable expressivity of the NF1 phenotype.
Collapse
Affiliation(s)
- I Eisenbarth
- Abteilung Humangenetik, Universität Ulm, Albert-Einstein-Allee 11, D-89081 Ulm, Germany.
| | | | | | | |
Collapse
|
29
|
Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, Moose R, Virdi G, Roux K, Bauer M, Rojiani AM, Maria BL, Muir D, Wallace MR. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 2000. [DOI: 10.1002/1098-2264(200008)28:4<425::aid-gcc8>3.0.co;2-e] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
|
30
|
Natacci F, Colapietro P, Riva P, Corrado L, Rossi LN, Maninetti MM, Casciati MC, Zambrino CA, Lanzi G, Larizza L. Distribution and high frequency of novel alleles at NF1 polymorphic markers in the Italian population. Mol Cell Probes 1999; 13:415-20. [PMID: 10657145 DOI: 10.1006/mcpr.1999.0268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Segregation analysis of Neurofibromatosis type 1 (NF1) intragenic polymorphisms is a useful diagnostic tool for linkage analysis in familial cases and for the exclusion/detection of deletion in sporadic patients. We performed a segregation analysis of intragenic NF1 polymorphic markers in an Italian NF1 population consisting of 17 familial and 41 sporadic cases, for a total of 79 affected and 105 unaffected individuals. The haplotype in linkage with the mutation could be identified in all of the familial cases. Furthermore, an intragenic deletion was found in one sporadic case and confirmed by means of FISH using an NF1 IVS27 specific probe generated by a novel PCR procedure. In order to determine the allele frequencies at four NF1 polymorphisms in the Italian population, the unaffected family members and 25 unrelated Italian individuals were genotyped. Allele frequencies were found to be statistically different from those in the literature for markers IVS27AC28.4 and IVS38GT53.0. In addition four novel alleles were found in four unrelated subjects, and we observed a mutation during paternal gametogenesis in one case. These data suggest that NF1 polymorphic intragenic loci are unstable. It is unclear whether or not their marked instability may enhance the high mutation rate of the NF1 gene.
Collapse
Affiliation(s)
- F Natacci
- Department of Biology and Genetics, Medical Faculty, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
Tumor suppressor genes have a diversity of functions, but they have in common the property of inhibiting neoplastic transformation. When they become inactivated, a constraint is removed that allows cells to grow inappropriately. Mutations in these genes are now thought to be the initiating events in most cancers. The first tumor suppressor gene was discovered through its role in retinoblastoma, and many other tumor suppressor genes also have important ophthalmic manifestations. The first group of tumor suppressor genes to be discussed are those involved in retinoblastoma and uveal melanoma. These are among the most frequently mutated genes in human cancer and are key regulators of growth and homeostasis. The second group of genes is associated with specific hereditary tumor syndromes with ophthalmic manifestations. These genes function in a variety of molecular pathways and are associated with neoplastic and non-neoplastic abnormalities in restricted tissue distributions. Research on tumor suppressor genes continues to shed light on the molecular pathophysiology of ophthalmic tumors and will increasingly yield diagnostic and therapeutic applications.
Collapse
Affiliation(s)
- J W Harbour
- Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
| |
Collapse
|
32
|
Messiaen LM, Callens T, Roux KJ, Mortier GR, De Paepe A, Abramowicz M, Pericak-Vance MA, Vance JM, Wallace MR. Exon 10b of the NF1 gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing. Genet Med 1999; 1:248-53. [PMID: 11258625 DOI: 10.1097/00125817-199909000-00002] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
PURPOSE To analyze the spectrum and frequency of NF1 mutations in exon 10b. METHODS Mutation and sequence analysis was performed at the DNA and cDNA level. RESULTS We identified nine exon 10b mutations in 232 unrelated patients. Some mutations were recurrent (Y489C and L508P), others were unique (1465-1466insC and IVS10b+2delTAAG). Surprisingly, at the RNA level, Y489C causes skipping of the last 62 nucleotides of exon 10b. Another recurrent mutation, L508P, is undetectable by the Protein Truncation Test. CONCLUSION As exon 10b shows the highest mutation rate yet found in any of the 60 NF1 exons, it should be implemented with priority in mutation analysis.
Collapse
Affiliation(s)
- L M Messiaen
- Department of Medical Genetics, University Hospital, Gent, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ars E, Kruyer H, Gaona A, Serra E, Lázaro C, Estivill X. Prenatal diagnosis of sporadic neurofibromatosis type 1 (NF1) by RNA and DNA analysis of a splicing mutation. Prenat Diagn 1999. [DOI: 10.1002/(sici)1097-0223(199908)19:8<739::aid-pd626>3.0.co;2-a] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
34
|
Abstract
As knowledge of pathophysiology grows, so does the refinement of diagnoses. Sometimes increased knowledge permits consolidation and unification. Unfortunately, at our present level of understanding, it usually demands proliferation of diagnostic categories. As tedious as this diagnostic splintering may seem, such is the price currently exacted of both the investigator and the clinician who seek to optimise management. Increased diagnostic refinement often requires inquiry into matters outside the bounds of one's specialty. Most often we turn to the radiologist or to the laboratory to narrow the differential diagnosis generated from the history and neurological examination. As we have shown, a useful intermediate step is extension of the physical examination to organs such as the skin, which are not the traditional preserve of the neurologist. That any text could confer the sophistication required for expert dermatological diagnosis is an unrealistic expectation. However, we hope that this review will encourage careful examination of the skin, hair, and nails by the neurological practitioner, with consideration of referral to a dermatologist when greater expertise is required.
Collapse
Affiliation(s)
- O Hurko
- Neuroscience Research, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK.
| | | |
Collapse
|